Inhibition of Invasion and Angiogenesis by Zinc-Chelating Agent Disulfiram

Molecular Pharmacology

Volumn 64, Issue 5, 2003, Pages 1076-1084

  Shiah, Shine Gwo ^a   Kao, Yu Rung ^a   Wu, Felicia Ying Hsiueh ^b   Wu, Cheng Wen ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b ACADEMIA SINICA   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; DISULFIRAM; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; NUCLEOCAPSID PROTEIN; ZINC;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL INVASION; COLLAGEN DEGRADATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; EMBRYO; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR CELL;

ANIMALS; CHELATING AGENTS; CHICKENS; DISULFIRAM; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED;

EID: 0142148099     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.5.1076     Document Type: Article

References (40)

1. Brooks PC, Clark RA, and Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (Wash DC) 264:569-571.
2. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, and Cheresh DA (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683-693.
3. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, and Carmichael J (1993) Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85:574-578.
4. Chick J (1999) Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 20:427-435.
5. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R, and Wu CW (1997) Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 17:353-360.
6. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, et al. (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (Lond) 374:569-571.
7. Duffy MJ (1992) The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10:145-155.
8. Folkman J (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71.
9. Garbutt JC, West SL, Carey TS, Lohr KN, and Crews FT (1999) Pharmacological treatment of alcohol dependence: a review of the evidence. J Am Med Assoc 281:1318-1325.
10. Goetzl EJ, Banda MJ, and Leppert D (1996) Matrix metalloproteinases in immunity. J Immunol 156:1-4.
11. Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
12. Hendrix MJ, Seftor EA, Seftor RE, and Fidler IJ (1987) A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 38:137-147.
13. Heussen C and Dowdle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102:196-202.
14. Hogg PJ (2002) Biological regulation through protein disulfide bond cleavage. Redox Rep 7:71-77.
15. Johansson B (1992) A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 369:15-26.
16. Johnsen M, Lund LR, Romer J, Almholt K, and Dano K (1998) Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 10:667-671.
17. Johnson MD, Kim HR, Chesler L, Tsao-Wu G, Bouck N, and Polverini PJ (1994) Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160:194-202.
18. Kahari VM and Saarialho-Kere U (1999) Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31:34-45.
19. Khokha R and Waterhouse P (1994) The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction. J Neurooncol 18:123-127.
20. Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler-Stevenson WG, and Liotta LA (1994) Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 269:21505-21511.
21. Lakka SS, Jasti SL, Gondi C, Boyd D, Chandrasekar N, Dinh DH, Olivero WC, Gujrati M, and Rao JS (2002) Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 21:5601-5608.
22. Lane JE, Ribeiro-Rodrigues R, Suarez CC, Bogitsh BJ, Jones MM, Singh PK, and Carter CE (1996) In vitro trypanocidal activity of tetraethylthiuram disulfide and sodium diethylamine-N-carbodithioate on Trypanosoma cruzi. Am J Trop Med Hyg 55:263-266.
23. Liotta LA, Steeg PS, and Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336.
24. Liu GY, Frank N, Bartsch H, and Lin JK (1998) Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFkappaB, c-fos/c-jun and p53 proteins. Mol Carcinog 22:235-246.
25. Marikovsky M, Nevo N, Vadai E, and Harris-Cerruti C (2002) Cu/Zn superoxide dismutase plays a role in angiogenesis. Int J Cancer 97:34-41.
26. McDonnell NB, De Guzman RN, Rice WG, Turpin JA, and Summers MF (1997) Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS. J Med Chem 40:1969-1976.
27. Nash T and Rice WG (1998) Efficacies of zinc-finger-active drugs against Giardia lamblia. Antimicrob Agents Chemother 42:1488-1492.
28. Neims AH, Coffey DS, and Hellerman L (1966) A sensitive radioassay for sulfhydryl groups with tetraethylthiuram disulfide. J Biol Chem 241:3036-3040.
29. Ploemen JP, van Iersel ML, Wormhoudt LW, Commandeur JN, Vermeulen NP, and van Bladeren PJ (1996) In vitro inhibition of rat and human glutathione S-transferase isoenzymes by disulfiram and diethyldithiocarbamate. Biochem Pharmacol 52:197-204.
30. Reunanen N, Li SP, Abonen M, Foschi M, Han J, and Kahari VM (2002) Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J Biol Chem 277:32360-32368.
31. Rice WG, Supko JG, Malspeis L, Buckheit RW Jr, Clanton D, Bu M, Graham L, Schaeffer CA, Turpin JA, Domagala J, et al. (1995) Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science (Wash DC) 270:1194-1197.
32. Scheibel LW, Adler A, and Trager W (1979) Tetraethylthiuram disulfide (Antabuse) inhibits the human malaria parasite Plasmodium falciparum. Proc Natl Acad Sci USA 76:5303-5307.
33. Seftor RE, Seftor EA, De Larco JE, Kleiner DE, Leferson J, Stetler-Stevenson WG, McNamara TF, Golub LM, and Hendrix MJ (1998) Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 16:217-225.
34. Sliva D, English D, Lyons D, and Lloyd FP Jr (2002) Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun 290:552-557.
35. Stetler-Stevenson WG, Aznavoorian S, and Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541-573.
36. Talbot DC and Brown PD (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A:2528-2533.
37. Woessner JF Jr (1994) The family of matrix metalloproteinases. Ann N Y Acad Sci 732:11-21.
38. Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A, and Hawkins MJ (1996) Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Investig New Drugs 14:193-202.
39. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA and Hawkins MJ (1998) Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 16:2150-2156.
40. Zucker S, Lysik RM, Zarrabi MH, and Moll U (1993) M(r) 92, 000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 53:140-146.